+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Yumanity Therapeutics Inc (YMTX) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 47 Pages
  • December 2022
  • GlobalData
  • ID: 4278570
Yumanity Therapeutics Inc (YMTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Yumanity Therapeutics Inc (Yumanity), formerly Proteostasis Therapeutics Inc, is a clinical stage development company focused on the development of treatments for neurodegenerative diseases. The company uses its drug discovery platform for the development of its pipeline products. Yumanity's pipeline product candidates include YTX-7739 for the treatment of Parkinson's disease; YTX-9184 for the treatment of dementia with lewy bodies. Other pipeline also comprises of additional programs with undisclosed product candidates that are focused on frontotemporal lobar dementia (FTLD), amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. Yumanity is headquartered in Boston, Massachusetts, the US.

Yumanity Therapeutics Inc Key Recent Developments

  • Nov 14, 2022: Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
  • Aug 04, 2022: Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
  • Jun 28, 2022: Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer
  • May 13, 2022: Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Yumanity Therapeutics Inc - Key Facts
  • Yumanity Therapeutics Inc - Key Employees
  • Yumanity Therapeutics Inc - Key Employee Biographies
  • Yumanity Therapeutics Inc - Major Products and Services
  • Yumanity Therapeutics Inc - History
  • Yumanity Therapeutics Inc - Company Statement
  • Yumanity Therapeutics Inc - Locations And Subsidiaries
  • Head Office
Section 2 - Company Analysis
  • Company Overview
  • Yumanity Therapeutics Inc - Business Description
  • R&D Overview
  • Yumanity Therapeutics Inc - Corporate Strategy
  • Yumanity Therapeutics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Yumanity Therapeutics Inc - Strengths
  • Yumanity Therapeutics Inc - Weaknesses
  • Yumanity Therapeutics Inc - Opportunities
  • Yumanity Therapeutics Inc - Threats
  • Yumanity Therapeutics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Yumanity Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Yumanity Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Yumanity Therapeutics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Nov 14, 2022: Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
  • Aug 04, 2022: Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
  • Jun 28, 2022: Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer
  • May 13, 2022: Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments
  • Mar 25, 2022: Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments
  • Jan 11, 2022: Yumanity’s approach to neurodegenerative diseases validated by two external collaborations
  • Nov 16, 2021: Yumanity Therapeutics to Present at Multiple Upcoming November Investor Conferences
  • Nov 15, 2021: Yumanity Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
  • Aug 16, 2021: Yumanity Therapeutics Appoints Michael D. Wyzga as Chief Financial Officer and Announces Inducement Grants
  • Aug 13, 2021: Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Yumanity Therapeutics Inc, Key Facts
  • Yumanity Therapeutics Inc, Key Employees
  • Yumanity Therapeutics Inc, Key Employee Biographies
  • Yumanity Therapeutics Inc, Major Products and Services
  • Yumanity Therapeutics Inc, History
  • Yumanity Therapeutics Inc, Key Competitors
  • Yumanity Therapeutics Inc, Ratios based on current share price
  • Yumanity Therapeutics Inc, Annual Ratios
  • Yumanity Therapeutics Inc, Interim Ratios
  • Yumanity Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Yumanity Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Yumanity Therapeutics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Yumanity Therapeutics Inc, Performance Chart (2017 - 2021)
  • Yumanity Therapeutics Inc, Ratio Charts
  • Yumanity Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Yumanity Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Vertex Pharmaceuticals Inc
  • Novartis AG
  • AbbVie Inc
  • Eloxx Pharmaceuticals Inc
  • Eloxx Pharmaceuticals Inc
  • Tranquis Therapeutics Inc
  • Vertex Pharmaceuticals Inc
  • AbbVie Inc
  • Flatley Discovery Lab
  • Novartis AG
  • Bayer AG
  • Gilead Sciences Inc
  • Flatley Discovery Lab
  • Tranquis Therapeutics Inc
  • Gilead Sciences Inc
  • Bayer AG